01:15 PM EST - MYND Life Sciences : Announced it has entered into a non-binding memorandum of understanding to acquire all the issued and outstanding shares of Tidal Care Inc.o/a Tidal Psychedelics. Tidal is a vertically integrated psilocybin company with access to a $10 million leasehold facility purpose built for cannabis and mycelium cultivation. The primary goal of the combined entity is to provide MYND's highly sophisticated intellectual property portfolio with access to additional capital, and a diverse and an experienced management team to advance the Company's research and development initiatives. MYND Life Sciences
shares C.MYND are trading unchanged at $0.13.
